About 4 results found for searched term "KALA" (0.158 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3622 | Vernakalant | Potassium Channel |
| RSD-1235 | ||
| Vernakalant (RSD-1235) is an investigational mixed ion channel blocker, which can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents. | ||
| M6052 | Vernakalant HCl | Potassium Channel |
| RSD1235 hydrochloride | ||
| Vernakalant Hcl(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic. | ||
| M25488 | KALA | Peptides |
| KALA is an amphiphilic peptide that forms an α-helical structure. KALA modifies a plasmid DNA-encapsulating liposomal membrane and is used as a fusogenic peptide in order to achieve effective liver targeting and transfection of DNA via galactose receptors. | ||
| M29461 | Bafrekalant | Others |
| Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
